Abstract Body

Background: Antiretroviral (ARV) regimen simplification can improve treatment adherence and quality of life. We report the Week (W) 48 results of a prospective, randomized, open-label, ongoing Phase 3b trial of a regimen simplification to the single-tablet regimen elvitegravir/cobicistat/emtricitabine/ tenofovir DF (E/C/F/TDF) from ritonavir-boosted protease inhibitor (PI+RTV) plus emtricitabine/tenofovir DF (FTC/TDF) regimens. Methodology: Virologically suppressed subjects on PI+RTV + FTC/TDF regimens for ≥ 6 months were randomized (2:1) to switch to E/C/F/TDF or remain on their baseline PI regimen (i.e. PI). Eligibility criteria included CrCl ≥ 70 mL/min, no documented resistance to FTC and TDF, exposure to no more than 2 prior ARV regimens, and no history of virologic failure. The primary endpoint was the proportion of subjects who maintained HIV-1 RNA < 50 c/mL at W48 by FDA snapshot algorithm (12% noninferiority margin). If noninferiority was established, then superiority would be tested per a prespecified sequential testing procedure. Results: A total of 433 subjects (86% male, 19% non-white, 18% age ≥ 50 years) were randomized and treated (293 E/C/F/TDF; 140 PI). At randomization, RTV-boosted atazanavir (40%) and RTV-boosted darunavir (40%) were the most common PIs used; median years since first ARV use was 3; 19% were on their second ARV regimen. Baseline characteristics were similar between the two groups. At W48, 94% of subjects on E/C/F/TDF maintained HIV-RNA < 50 c/mL compared to 87% on PI (difference 6.7%, 95% CI +0.4% to +13.7%; p=0.025). Rates of virologic failure were low (0.7% E/C/F/TDF vs 1.4% PI) with no emergent resistance in either group. The safety and tolerability profiles of E/C/F/TDF were consistent with those reported in previous studies. Grade 2-4 drug-related adverse events (AEs) were 3.8% E/C/F/TDF vs 1.4% PI. AEs leading to drug discontinuation were low, 2.0% vs 2.9% respectively. At W48, median changes in CrCl (mL/min) were -7.5 and 0.4, respectively, with no cases of proximal renal tubulopathy in either group. There was a larger decrease from baseline in fasting triglycerides for E/C/F/TDF compared to PI (median: -16 vs +3 mg/dL; p =0.001) and no change in other lipid parameters. Conclusions: Switching to E/C/F/TDF compared to continuing PI+RTV+FTC/TDF resulted in significantly higher rates of virologic suppression without emergence of resistance. E/C/F/TDF was well-tolerated with a favorable safety profile. Switching to E/C/F/TDF from a multiple-tablet, PI-based regimen may be an option for patients wishing to simplify their ARV therapy.